AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN (TSLP)-RECEPTOR SIGNALING
The present disclosure is related to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules may have modified Fc regions that increase antibody half-life, increase resistance to prote...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TAM, SUSAN ZHANG, DI SHI, LIHUA FUNG, MANONG |
| description | The present disclosure is related to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules may have modified Fc regions that increase antibody half-life, increase resistance to proteases, and/or reduce ability to interact with Fc gamma receptors. These molecules are useful for treatment of allergic and non-allergic inflammation associated with TSLP-related disorders and diseases.
La présente invention concerne des anticorps (par exemple, des anticorps humains) et des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement et neutralisent la lymphopoïétine stromale thymique (TSLP) (humaine). De telles molécules peuvent avoir des régions Fc modifiées qui augmentent la demi-vie de l'anticorps, augmentent la résistance aux protéases et/ou réduisent la capacité d'interagir avec les récepteurs gamma Fc. Ces molécules sont utiles pour le traitement d'une inflammation allergique et non allergique associée à des troubles et maladies liés à la TSLP. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3147044A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3147044A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3147044A13</originalsourceid><addsrcrecordid>eNqNyr0KwjAUQOEsDqK-wx11KFgacA7hNrmQP5MLpVMpEifRQn1_dPABnA58nK24KoOBC7BVDBQYc48ZYSC2Xxs9aSico1cO3OiTjSkSMgU4cnHp1GTUmDhmKGSCchTMXmzu82Oth193AnpkbZu6vKa6LvOtPut70qpr5eUspWq7P5YPb5YvIQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN (TSLP)-RECEPTOR SIGNALING</title><source>esp@cenet</source><creator>TAM, SUSAN ; ZHANG, DI ; SHI, LIHUA ; FUNG, MANONG</creator><creatorcontrib>TAM, SUSAN ; ZHANG, DI ; SHI, LIHUA ; FUNG, MANONG</creatorcontrib><description>The present disclosure is related to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules may have modified Fc regions that increase antibody half-life, increase resistance to proteases, and/or reduce ability to interact with Fc gamma receptors. These molecules are useful for treatment of allergic and non-allergic inflammation associated with TSLP-related disorders and diseases.
La présente invention concerne des anticorps (par exemple, des anticorps humains) et des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement et neutralisent la lymphopoïétine stromale thymique (TSLP) (humaine). De telles molécules peuvent avoir des régions Fc modifiées qui augmentent la demi-vie de l'anticorps, augmentent la résistance aux protéases et/ou réduisent la capacité d'interagir avec les récepteurs gamma Fc. Ces molécules sont utiles pour le traitement d'une inflammation allergique et non allergique associée à des troubles et maladies liés à la TSLP.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210114&DB=EPODOC&CC=CA&NR=3147044A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210114&DB=EPODOC&CC=CA&NR=3147044A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TAM, SUSAN</creatorcontrib><creatorcontrib>ZHANG, DI</creatorcontrib><creatorcontrib>SHI, LIHUA</creatorcontrib><creatorcontrib>FUNG, MANONG</creatorcontrib><title>AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN (TSLP)-RECEPTOR SIGNALING</title><description>The present disclosure is related to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules may have modified Fc regions that increase antibody half-life, increase resistance to proteases, and/or reduce ability to interact with Fc gamma receptors. These molecules are useful for treatment of allergic and non-allergic inflammation associated with TSLP-related disorders and diseases.
La présente invention concerne des anticorps (par exemple, des anticorps humains) et des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement et neutralisent la lymphopoïétine stromale thymique (TSLP) (humaine). De telles molécules peuvent avoir des régions Fc modifiées qui augmentent la demi-vie de l'anticorps, augmentent la résistance aux protéases et/ou réduisent la capacité d'interagir avec les récepteurs gamma Fc. Ces molécules sont utiles pour le traitement d'une inflammation allergique et non allergique associée à des troubles et maladies liés à la TSLP.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyr0KwjAUQOEsDqK-wx11KFgacA7hNrmQP5MLpVMpEifRQn1_dPABnA58nK24KoOBC7BVDBQYc48ZYSC2Xxs9aSico1cO3OiTjSkSMgU4cnHp1GTUmDhmKGSCchTMXmzu82Oth193AnpkbZu6vKa6LvOtPut70qpr5eUspWq7P5YPb5YvIQ</recordid><startdate>20210114</startdate><enddate>20210114</enddate><creator>TAM, SUSAN</creator><creator>ZHANG, DI</creator><creator>SHI, LIHUA</creator><creator>FUNG, MANONG</creator><scope>EVB</scope></search><sort><creationdate>20210114</creationdate><title>AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN (TSLP)-RECEPTOR SIGNALING</title><author>TAM, SUSAN ; ZHANG, DI ; SHI, LIHUA ; FUNG, MANONG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3147044A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>TAM, SUSAN</creatorcontrib><creatorcontrib>ZHANG, DI</creatorcontrib><creatorcontrib>SHI, LIHUA</creatorcontrib><creatorcontrib>FUNG, MANONG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TAM, SUSAN</au><au>ZHANG, DI</au><au>SHI, LIHUA</au><au>FUNG, MANONG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN (TSLP)-RECEPTOR SIGNALING</title><date>2021-01-14</date><risdate>2021</risdate><abstract>The present disclosure is related to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules may have modified Fc regions that increase antibody half-life, increase resistance to proteases, and/or reduce ability to interact with Fc gamma receptors. These molecules are useful for treatment of allergic and non-allergic inflammation associated with TSLP-related disorders and diseases.
La présente invention concerne des anticorps (par exemple, des anticorps humains) et des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement et neutralisent la lymphopoïétine stromale thymique (TSLP) (humaine). De telles molécules peuvent avoir des régions Fc modifiées qui augmentent la demi-vie de l'anticorps, augmentent la résistance aux protéases et/ou réduisent la capacité d'interagir avec les récepteurs gamma Fc. Ces molécules sont utiles pour le traitement d'une inflammation allergique et non allergique associée à des troubles et maladies liés à la TSLP.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3147044A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN (TSLP)-RECEPTOR SIGNALING |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T13%3A31%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TAM,%20SUSAN&rft.date=2021-01-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3147044A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |